Bye bye biosimilars: Big Pharma’s imminent exit in sight, says expert
As prices drop, Big Pharma will exit the biosimilar space over the next five to 10 years, says industry expert Sarfaraz Niazi. Amgen, Novartis and Pfizer refute the claim, saying they are in the sector for the long-term. Blockbuster biologic originator companies are, by definition, Big Pharma fir ...
The New Inspection Protocol Project (NIPP) intends to increase the speed and efficiency of sterile injectable facility inspections through the se ...
South Korea’s financial regulator has concluded Samsung BioLogics inflated its value ahead of its initial public offering (IPO) in 2016. The CD ...
The cell and gene therapy tool supplier space is ripe for consolidation says BioLife Solutions, which is evaluating several acquisition targets.
...
Abzena will have two 500 L bioreactors and one 2,000 L bioreactor supplied by Sartorius at its San Diego facility once additional capacity comes ...
Recent Tweets
-
Samsung BioLogics vows to prove innocence as trading suspended https://t.co/q48yotQsnA
4 hours ago
-
Korea’s financial regulator has concluded Samsung BioLogics inflated its value ahead of its IPO in 2016. The #CDMO… https://t.co/lRd5Ag9iQo
1 hour ago
-
RT @BioProcessIntl: RT @dan5tanton at @BioProInsider : As prices drop, Big Pharma will exit #biosimilars over the next 5 to 10 years, s… https://t.co/jLjUFeidzp
5 days ago
-
RT @Dan5tanton: CDMO Catalent pumping $200m into biomanufacturing expansions in Wisconsin and Indiana https://t.co/i4c1CoOxJT
7 days ago
Trending
Business
BioProcess International Conference and Exhibition 2018 Postevent Report: Key Insights, Highlights, and Take-Away Messages
Manufacturing
Development of a Standardized Extractables Approach for Single-Use Components: General Considerations and Practical Aspects — A Manufacturer's Perspective
Analytical
Viral Risk Mitigation: A Global Regulatory Perspective
Downstream Processing
Inactivation of Enveloped Viruses: Seeking Alternatives to a Problematic Surfactant